Cargando…

Real-life use of vasopressors and inotropes in cardiogenic shock—observation is necessarily ‘theory-laden’

Detalles Bibliográficos
Autores principales:	Ray, Samiran, Cvetkovic, Mirjana, Lutman, Daniel H., Pathan, Nazima, Ramnarayan, Padmanabhan, Inwald, David P., Peters, Mark J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036283/ https://www.ncbi.nlm.nih.gov/pubmed/27666427 http://dx.doi.org/10.1186/s13054-016-1473-4

Ejemplares similares

Vasopressors and inotropes in cardiogenic shock: is there room for “adrenaline resuscitation”?
por: Morici, Nuccia, et al.
Publicado: (2016)

State of Shock: Contemporary Vasopressor and Inotrope Use in Cardiogenic Shock
por: Bloom, Jason E., et al.
Publicado: (2023)

The Usage of Concomitant Beta-Blockers with Vasopressors and Inotropes in Cardiogenic Shock
por: Ryu, Rachel, et al.
Publicado: (2022)

Vasopressor stays vasopressor and inotrope stays inotrope!
por: Luckner, Günter, et al.
Publicado: (2008)

Vasopressors and Inotropes in Acute Myocardial Infarction Related Cardiogenic Shock: A Systematic Review and Meta-Analysis
por: Karami, Mina, et al.
Publicado: (2020)

Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenaline use is associated with excess organ injury and mortality
por: Tarvasmäki, Tuukka, et al.
Publicado: (2016)

Vasopressors and Inotropes in the Treatment of Human Septic Shock: Effect on Innate Immunity?
por: Hartemink, Koen J., et al.
Publicado: (2011)

Predictors of In-hospital Mortality in Cardiogenic Shock Patients on Vasoactive or Inotropic Support
por: Nandkeolyar, Shuktika, et al.
Publicado: (2021)

Inotropic support in cardiogenic shock: who leads the battle, milrinone or dobutamine?
por: Lozada Martinez, Ivan David, et al.
Publicado: (2022)

Dopamine versus norepinephrine as the first-line vasopressor in the treatment of cardiogenic shock
por: Na, Soo Jin, et al.
Publicado: (2022)

Cerebral Effects of Commonly Used Vasopressor-Inotropes: A Study in Newborn Piglets
por: Hahn, Gitte H., et al.
Publicado: (2013)

Current use of inotropes in circulatory shock
por: Scheeren, Thomas W. L., et al.
Publicado: (2021)

VASOPRESSOR-RESISTANT HYPOTENSION, COMBINATION VASOPRESSOR THERAPY, AND SHOCK PHENOTYPES IN CRITICALLY ILL ADULTS WITH VASODILATORY SHOCK
por: Priyanka, Priyanka, et al.
Publicado: (2022)

Impact of baseline beta-blocker use on inotrope response and clinical outcomes in cardiogenic shock: a subgroup analysis of the DOREMI trial
por: Di Santo, Pietro, et al.
Publicado: (2021)

“Assessing the hemodynamic impact of various inotropes combination in patients with cardiogenic shock with Non-ST elevation myocardial infarction –the ANAPHOR study”
por: Sharma, Kamal, et al.
Publicado: (2021)

Threshold of Inotropic Score and Vasoactive–Inotropic Score for Predicting Mortality in Pediatric Septic Shock
por: Kallekkattu, Dipu, et al.
Publicado: (2021)

Current use of vasopressors in septic shock
por: Scheeren, Thomas W. L., et al.
Publicado: (2019)

Vasopressors in Septic Shock: The Quest for Refinement
por: Pichamuthu, Kishore
Publicado: (2022)

Inotrope Use and Intensive Care Unit Mortality in Patients With Cardiogenic Shock: An Analysis of a Large Electronic Intensive Care Unit Database
por: Gao, Fei, et al.
Publicado: (2021)

Vasopressor requirement during targeted temperature management for out-of-hospital cardiac arrest caused by acute myocardial infarction without cardiogenic shock
por: Song, Gyuho, et al.
Publicado: (2016)

Choice of vasopressor in septic shock: does it matter?
por: Patel, Gourang P, et al.
Publicado: (2007)

Fluids or vasopressors for the initial resuscitation of septic shock
por: Macdonald, Stephen, et al.
Publicado: (2022)

Effect of induction agent on vasopressor and steroid use, and outcome in patients with septic shock
por: Ray, David Charles, et al.
Publicado: (2007)

Phenotyping cardiogenic shock that showed different clinical outcomes and responses to vasopressor use: a latent profile analysis from MIMIC-IV database
por: Yu, Yue, et al.
Publicado: (2023)

Cardiogenic shock /
Publicado: (2002)

Cardiogenic Shock
por: Vahdatpour, Cyrus, et al.
Publicado: (2019)

Influence of vasopressor agent in pediatric septic shock mortality
por: Mangia, CMF, et al.
Publicado: (2011)

Does vasopressor therapy have an indication in hemorrhagic shock?
por: Beloncle, François, et al.
Publicado: (2013)

Therapeutic Strategies for High-Dose Vasopressor-Dependent Shock
por: Bassi, Estevão, et al.
Publicado: (2013)

Vasopressors: Do they have any role in hemorrhagic shock?
por: Gupta, Babita, et al.
Publicado: (2017)

Vasopressors in septic shock: which, when, and how much?
por: Shi, Rui, et al.
Publicado: (2020)

Adjunctive vasopressors in distributive shock: How soon is early?
por: Garcia, Bruno, et al.
Publicado: (2023)

Cohort profile of the Biomarkers of Acute Serious Illness in Children (BASIC) study: a prospective multicentre cohort study in critically ill children
por: Feinstein, Yael, et al.
Publicado: (2018)

Effect of Cardiogenic Shock Hospital Volume on Mortality in Patients With Cardiogenic Shock
por: Shaefi, Shahzad, et al.
Publicado: (2015)

Vasoactive-inotropic score and pediatric septic shock mortality: Correspondence
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

CARDIOGENIC SHOCK WITH IMIPRAMINE
por: Chaudhury, S., et al.
Publicado: (1990)

Hypothermia in cardiogenic shock
por: van der Pals, Jesper
Publicado: (2012)

Phenotyping Cardiogenic Shock
por: Zweck, Elric, et al.
Publicado: (2021)

Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis
por: Avni, Tomer, et al.
Publicado: (2015)

Outcome of patients with septic shock and high-dose vasopressor therapy
por: Auchet, Thomas, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fi03tsl7qcjbtqbrcd05dq5198